Introduction {#s1}
============

Venous thromboembolism (VTE) is a complex and common cardiovascular disease that includes deep venous thrombosis (DVT), cerebral infarction, and pulmonary embolism (PTE), which is caused by multiple factors. The incidence of VTE is around 0.1--0.2% in Caucasian and American populations ([@B4]). The hospitalization rates of VTE increased from 3.2 to 17.5 per 100,000 population, and the mortality decreased from 4.7% to 2.1% in China ([@B43]). The acquired or inherited risk factors for the development of VTE include surgery, pregnancy, and cancer ([@B16]; [@B20]). Familial cohort and case-control studies have demonstrated that VTE is often familial or hereditary ([@B29]; [@B19]). Over 60% of the variations in susceptibility to common thrombosis are attributable to genetic factors ([@B38]).

Genetic variations in coagulation system genes (such as *F5*, *PROC*, and *SERPINC1*) contribute to susceptibility to venous thrombosis ([@B15]; [@B35]). Protein C (PROC), protein S (PROS1), and antithrombin have been demonstrated to play important roles in the anticoagulation process ([@B25]). *SERPINC1* is the gene encoding antithrombin. Deficiency of antithrombin is usually caused by rare or private variations of *SERPINC1* gene. Deficiency among coagulation system factors can increase the risk of developing thrombosis. Inherited antithrombin deficiency is a rare, autosomal dominant disorder (MIM\#107300). Antithrombin exerts its physiological function by inhibiting procoagulation factors, such as thrombin, factor Xa, factor IIa, and other factors of the blood coagulation system ([@B42]). Antithrombin belongs to the serine protease inhibitor superfamily and regulates clot formation both by inhibiting thrombin activity directly and by interfering with earlier stages of the clotting cascade ([@B34]). There are two types of antithrombin deficiency. In type I antithrombin deficiency, functional and antigenic levels are proportionally decreased. In type II antithrombin deficiency, antigenic levels are normal while the functional activity is abnormal. In around 0.02--0.25% of a healthy population with antithrombin deficiency, there is a 5- to 50-fold increased risk of developing venous thrombosis ([@B45]; [@B23]; [@B28]).

The first variation linked to antithrombin deficiency was characterized in 1983 and, to date, more than 200 variants have been reported to be associated with the risk of thrombosis ([@B9]; [@B32]). The homozygous variant (Phe229Leu) of *SERPINC1* leading to spontaneous antithrombin polymerization *in vivo* has been shown to be associated with severe childhood thrombosis ([@B33]). The heterozygous variant is mainly associated with a high risk of venous thrombosis ([@B2]; [@B32]). However, most of these variants are rare and seldom replicate in other populations. rs2227589, a polymorphism of *SERPINC1* gene (NG_012462.1:g.5301G \> A), was found to be associated with the risk of venous thrombosis in a Dutch population ([@B5]). The minor allele frequencies of rs2227589 is 0.10 (gnomAD) and 0.329 in the East Asian population. Previous study of normal Spanish Caucasian showed a functional effect of the rs2227589 on antithrombin levels ([@B1]). The findings regarding the association between rs2227589 and antithrombin levels were inconsistent among different studies ([@B36]; [@B6]). Furthermore, the association between rs2227589 and the risk of VTE in Northern European, American, and Norwegian populations is inconsistent ([@B40]; [@B3]; [@B10]; [@B21]; [@B22]). The study of Jiang did not enroll a large sample size as in the study of [@B40] and showed negative results with publication bias ([@B21]). Similarly, another Swedish population study showed no significant association between rs2227589 and the risk of VTE ([@B7]). These findings imply that associations might differ between Western and Asian populations depending on ethnicity.

Given that the association between rs2227589 and the Chinese PTE population has not been examined, we performed this case-control study to investigate the association between variant rs2227589, antithrombin deficiency, and PTE risk in a Chinese population. Furthermore, a systematic review and a meta-analysis were carried out to evaluate the variant in antithrombin deficiency and VTE.

Materials and Methods {#s2}
=====================

Study Subjects {#s2_1}
--------------

A total of 98 patients with PTE, 3 patients with familial VTE, and 199 matched controls were recruited from the Second Clinical Medical College of Shenzhen People's Hospital from December 2013 to September 2017. The three familial VTE subjects were enrolled because each had more than two siblings who were diagnosed with PTE. Strict criterion was conducted to exclude the multiple PTE effected risk factors in this association analysis, such as cancer, diabetes, and so on. In this regard, only 101 cases were enrolled in our studies. The inclusion criteria for the PTE patients were the criteria released by the European Society of Cardiology (ESC) in 2014 ([@B24]). Most of the recruited subjects are unprovoked, recurrent, or inherited acute PTE. The healthy controls were recruited as described previously ([@B41]). Informed consent was obtained from each patient. Research and ethics approval was obtained from the ethics committee of Shenzhen People's Hospital. All procedures involving human participants were performed in accordance with the 1964 Declaration of Helsinki. Demographic characteristics and medical histories were recorded, including age and history of family disease.

Plasma Antithrombin Anticoagulant Activity Assay in PTE Subjects {#s2_2}
----------------------------------------------------------------

Blood samples were collected into trisodium citrate by venopuncture. Plasma samples were obtained by centrifugation at 2,000g for 15 min at 4°C and stored at -80°C until analysis. The antithrombin anticoagulant activity was determined by automatic chromogenic assay on the IL Coagulation systems according to the manufacturer's instructions (Cat.0020300400, Werfen, Bedford, MA). Briefly, the plasma was first incubated with Factor Xa reagent in the presence of an excess of heparin, followed by incubation with a synthetic chromogenic substrate. Quantification of the residual Factor Xa was performed by detecting the absorbance at 405 nm by ACLTOP 700 system (Werfen). The absorbance is inversely proportional to the antithrombin level in the test sample. The activation levels were calculated by the standard curve of each detection. The established normal range of plasma antithrombin levels was 83--128%, which was based on our hospital pathology reference from thousands of previously diagnosed clinical subjects.

DNA Preparation and Genotyping {#s2_3}
------------------------------

Genomic DNA was extracted from whole blood using QIAamp DNA Blood kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The candidate single-nucleotide polymorphism (SNP) was genotyped by MassARRAY SNP genotyping platform (Sequenom, San Diego, CA) among PTE case and control subjects. The following primers for polymerase chain reaction (PCR) amplification were used: forward, 5′-ACGTTGGATGGAAAGGCCTTACCCCAAGAG-3′ and reverse, 5′-ACGTTGGATGTCTCCCTGGTAGTTACAGTC-3′. The genotyping assay extension primers for SNP rs2227589 were 5′-GGAGAGCACTTGAAATGAT-3′. All primers were designed by Sequenom's MassARRAY Designer software. A specific primer extension was performed to detect single-base polymorphisms in the amplified DNA.

Systematic Review Analysis {#s2_4}
--------------------------

A systematic literature search was performed using PubMed, Science Direct, ISI Web of Knowledge, Google Scholar, and the CNKI Database, and the cutoff date was defined as January 2019. A meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ([@B30]). Search terms using the Boolean operators at PubMed included but were not limited to the following: "venous thrombosis" (MeSH Terms) OR VTE (All Fields) AND *SERPINC1* (MeSH Terms) OR rs2227589 (All Fields). Only case-control studies regarding an association between rs2227589 and VTE were considered eligible. The data extracted from the eligible studies included author, publication year, racial and genotype methods, and variants frequency. The control population genotype data of publications followed the Hardy-Weinberg equilibrium.

Eligibility Criteria and Data Validity Assessment {#s2_5}
-------------------------------------------------

The eligibility criteria of studies are according to our previous publication ([@B41]). The criterion for including eligible studies was that the DVT or PTE should be diagnosed with standard criteria in the case group. Only case-control studies regarding an association between rs2227589 and VTE were considered eligible. For exclusion, reviews, conference abstracts, republished or duplicate studies, and meta-analyses were not included. The data extracted from the eligible studies included author, publication year, racial and genotype methods, and variants frequency. The control population genotype data of publications followed the Hardy-Weinberg equilibrium. The validity of data was evaluated by three independent reviews. The genotype results of two eligible studies were not complete or available in the publications. Finally, the genotype data were kindly shared by professor Pierre-Emmanuel Morange ([@B40]), but the other study results were not obtained from the authors upon request ([@B17]).

Statistical Analysis and Meta-Analysis {#s2_6}
--------------------------------------

All statistical analyses were performed using software STATA 14.0 and SPSS 19 (IBM). The strength of association was evaluated by pooled odds ratio (OR) and 95% confidence interval (CI). Either a fixed-effects model (Mantel-Haenszel method) or a random-effects model was used for meta-analysis. The *z*-test was used to evaluate the significance of the pooled OR ([@B26]). Heterogeneity was tested using Cochran's Q statistic ([@B18]), and publication bias was tested using Egger's test ([@B13]; [@B39]). Nonparametric trim-and-fill method was performed to assess the possible effect of funnel plot asymmetry and publication bias in the meta-analysis ([@B12]). Sensitivity analysis was conducted by sequentially omitting one study at a time. Chi square and Bonferroni (*post hoc*) tests were used for cross-tabulation and multiple comparisons, respectively. P \< 0.05 was considered statistically significant.

Results {#s3}
=======

Demographics of the Participants {#s3_1}
--------------------------------

After filtering with the inclusion criteria and exclusion criteria, a total of 101 patients were enrolled for plasma antithrombin anticoagulant activity level assay in this study. The general characteristics of PTE patients are presented in [**Table 1**](#T1){ref-type="table"}. The mean age of the patients with PTE was 59 ± 1.7 years old. Antithrombin activity deficiency was present in 27 patients (26.7%) with venous thrombosis. The average level of active antithrombin was 90 ± 2.0%. The details of antithrombin anticoagulant activity in patients with PTE were presented in [**Supplemental Table S1**](#SM4){ref-type="supplementary-material"}.

###### 

Demographics of the participants and antithrombin anticoagulant activity in patients with pulmonary embolism.

  ---------------------------------------------------------------------------------------------------------
  Characteristic/Genotype   Number (%) or\   Antithrombin activity (Mean ± SEM)   *p* value
                            mean ± SEM                                            
  ------------------------- ---------------- ------------------------------------ -------------------------
  Gender\                   51/50                                                 
  Male/female(n)                                                                  

  Age (years)               59 ± 1.7                                              

  Total subjects            101              90 ± 2.0%                            83--128% (normal range)

  Deficiency case           27               62.9 ± 2.8%                          P \< 0.001

  Normal case               84               99.9 ± 1.4%                          

  rs2227589 genotype                                                              

  CC                        40 (39.6%)       91.6 ± 2.8%                          P \> 0.05

  CT                        45 (44.6%)       88.5 ± 3.5%                          

  TT                        16 (15.8%)       90.3 ± 4.6%                          
  ---------------------------------------------------------------------------------------------------------

Association of Genetic Models Between rs2227589 and PTE Risk {#s3_2}
------------------------------------------------------------

Allele and genotype frequencies of *SERPINC1* polymorphism (rs2227589) in PTE patients and controls are summarized in [**Figure 1**](#f1){ref-type="fig"} and [**Table 2**](#T2){ref-type="table"}. The genotypes of rs2227589 followed the Hardy-Weinberg equilibrium among the controls. In our study, the CT genotype (heterozygote) was 44.6%, which was much higher than in the previously reported ethnic cohorts (around 20%). Furthermore, homozygote SNPs were also present in the PTE group at a very high frequency (\>7%). The frequencies of the SNP homozygote and heterozygote were similar between the case and control groups. Carriers of *SERPINC1* polymorphism (rs2227589) were associated (P = 0.026) with an increased risk of PTE \[OR: 2.31, 95% CI (1.09--4.89)\], which was detected in the recessive model but not in the additive and dominant models ([**Table 3**](#T3){ref-type="table"}).

![Genotype distribution of rs2227589 in pulmonary embolism and normal subjects.](fgene-10-00844-g001){#f1}

###### 

Genotype distribution of *SERPINC1* polymorphism (rs2227589) among different studies.

  Author          Years   Ethnicity           Source    Case    Control   Methods                      
  --------------- ------- ------------------- --------- ------- --------- --------- ------- ----- ---- ----------
  Bezemer         2008    Netherlands         Mega2     1,001   278       15        2325    483   28   PCR
  Tregouet        2009    Northern European   GWAS      317     89        5         983     235   10   Beadchip
  Tregouet        2009    Northern European   MARTHA    922     228       12        621     149   12   Taqman
  Tregouet        2009    Northern European   FARIVE    478     111       5         467     119   1    Taqman
  Austin          2011    White America       White     426     113       5         530     127   7    Taqman
  Austin          2011    Black America       Black     469     58        2         499     71    5    Taqman
  El-Galaly, TC   2013    Danish              White     494     105       8         1,434   279   17   Taqman
  Rovite, V       2014    Latvia              Latvia    139     38        0         179     53    3    Taqman
  Kajuna, I       2018    Latvia              Latvia    82      17        0         71      27    1    Taqman
  Yue, YY         2019    Asian               Chinese   40      45        16        84      100   15   Sequenom

###### 

OR, 95% CIs, and antithrombin activity levels in three genetic models of rs2227589 among patients with pulmonary embolism.

  Genetic models   Pooled effect    Antithrombin activity                                       
  ---------------- ---------------- ----------------------- ------- --------------------------- ------
  Additive         T vs. C          1.27 (0.89--1.81)       0.18    88.9 ± 2.9 vs. 89.9 ± 2.3   0.79
  Dominant         TT + TC vs. CC   1.11 (0.68--1.81)       0.67    89.0 ± 2.9 vs. 91.6 ± 2.8   0.25
  Recessive        TT vs. TC + CC   2.31 (1.09--4.89)       0.026   86.8 ± 3.7 vs. 90.6 ± 2.3   0.5

Association Assay Between Plasma Antithrombin Anticoagulant Activity and Frequency of rs2227589 Carriers {#s3_3}
--------------------------------------------------------------------------------------------------------

The correlation between rs2227589 and antithrombin anticoagulant activity of PTE was also evaluated. Among rs2227589 carriers, 16 (16/61) showed antithrombin deficiency compared with noncarriers (11/40) ([**Table 1**](#T1){ref-type="table"}). Only 4 subjects showed antithrombin deficiency among the 16 homozygote SNP carriers. There was no significant difference in antithrombin activity levels among the three rs2227589 genotype groups. Carriers of the TT alleles had slightly lower anticoagulant activity than did carriers of the CC alleles, but this was not statistically significant (P = 0.45). We also checked whether significant differences existed among the associated recessive genetic model groups (CC + CT vs. TT). The results showed that the T allele carriers had slightly lower antithrombin activity, but this was not statistically significant ([**Table 3**](#T3){ref-type="table"}).

Meta-Analysis for the Association Between rs2227589 and VTE Risk in Different Populations {#s3_4}
-----------------------------------------------------------------------------------------

The genotyping data of rs2227589 in 101 Chinese PTE patients of our case-control study were enrolled in the meta-analysis. In pooled systematic analysis, 10 case-control cohorts from six studies were enrolled. The total numbers of VTE-affected patients and controls were 5,518 and 8,935, respectively. The characteristics, genotype distribution, and allelic frequencies of the eligible studies are displayed in [**Table 2**](#T2){ref-type="table"}. The meta-analysis was carried out using the additive, recessive, and dominant genetic models. The heterogeneity value was less than 50% (P \> 0.05), indicating that our study had low heterogeneity and that a fixed model could be used in the analysis ([**Table 4**](#T4){ref-type="table"}). The association effect distribution is presented as forest plots ([**Figure 2**](#f2){ref-type="fig"}, [**Supplementary Figure S1**](#SM1){ref-type="supplementary-material"}). The association effect of pooled OR with the additive model was 1.09 (95% CI 1.01--1.18, P = 0.029) and the dominant model was 1.10 (95% CI 1.01--1.20, P = 0.034). Systematic analysis of previous cohort studies showed a significant association between rs2227589 and the risk of VTE under additive and dominant genetic models. Subgroups analysis of Caucasians showed consistent results of the association ([**Table 4**](#T4){ref-type="table"}). Furthermore, potential publication bias was examined by funnel and Galbraith plots ([**Figure 3**](#f3){ref-type="fig"}; [**Supplemental Figure S2**](#SM2){ref-type="supplementary-material"}). The results showed that there was no sharp asymmetry between the two models, which indicated no obvious potential bias among the enrolled publications. But Galbraith assay showed potential bias of additive and dominant models, which indicated that the bias may be caused by the small sample size or ethnic differences of enrolled cohorts. Thus, trim-and-fill method analysis was applied to correct publication bias. The results showed the pooled effect unchanged of the two genetic models and continued to be statistically significant, which indicated that the effect of bias is very slight with reliable conclusions ([**Supplemental Figure S3**](#SM3){ref-type="supplementary-material"}). Sensitivity analyses showed that the pooled ORs fluctuated among confidence intervals ([**Figure 4**](#f4){ref-type="fig"}), which suggested good reliability among our results and methods to provide an effective evaluation.

###### 

The results of pooled OR, 95% CIs, and heterogeneity by meta-analysis.

  Genetic models   Pooled effect           z                   Heterogeneity                 
  ---------------- ----------------------- ------------------- --------------- ------ ------ ------
  Additive         T vs. C                 1.09 (1.01--1.18)   0.029           2.18   44.3   0.06
                   Subgroups (Caucasian)   1.10 (1.01--1.20)   0.023           2.27   44.9   0.08
  Dominant         TT + TC vs. CC          1.10 (1.01--1.20)   0.034           2.21   40.1   0.09
                   Subgroups (Caucasian)   1.12 (1.02--1.22)   0.017           2.39   45.1   0.08
  Recessive        TT vs. TC + CC          1.17 (0.85--1.61)   0.328           0.98   16.4   0.29
                   Subgroups (Caucasian)   1.06 (0.74--1.52)   0.741           0.33   0.0    0.54

![Forest plots for the association between rs2227589 and the risk of venous thromboembolism among different populations **(A)**, additive model; **(B)** dominant model; **(C)** recessive model).](fgene-10-00844-g002){#f2}

![Funnel plot of bias examination in the additive model **(A)** and dominant model **(B)**.](fgene-10-00844-g003){#f3}

![Sensitivity analysis of rs2227589 and the risk of venous thromboembolism (VTE) in the additive model **(A)** and dominant model **(B)**.](fgene-10-00844-g004){#f4}

Discussion {#s4}
==========

Because of controversial results from GWAS and case-control studies of rs2227589, a prediction of the risk factors associated with developing VTE is unreliable. In this study, we explored the association between the variant rs2227589 with antithrombin deficiency and risk of PTE in a Chinese population. Our case-control study found a significant association between *SERPINC1* rs2227589 polymorphism and increased risk of PTE in the recessive model. Pooled systematic analysis of all cohorts showed a significant association in the additive and dominant genetic models. The association between rs2227589 and repeated episodes of VTE demonstrated a genetic risk with ethnic differences.

Inherited antithrombin deficiency is an autosomal dominant thrombotic disorder associated with potential risk factors for the development of DVT. Antithrombin is a plasma serine protease inhibitor that can progressively inactivate thrombin, FIIa, and FXa anticoagulation functions. A functional study of rare variations in *PROC*, *PROS1*, and *SERPINC1* genes or other coagulation factors suggests that rare variants may cause inherited deficiencies in the anticoagulant system. Previous studies in an Asian population reported that the incidence of antithrombin deficiency in VTE was around 5.9%--9.61% ([@B27]; [@B44]). Most VTE subjects with antithrombin deficiency have been found to carry genetic variants of *SERPINC1* ([@B42]; [@B31]). However, the functional mechanism of variant rs2227589 underlying the levels of antithrombin in plasma remains largely unknown ([@B1]).

Our studies showed that the incidence of antithrombin deficiency is 26.7% in PTE. In our study, the definition of antithrombin deficiency was based on our established antithrombin deficiency normal range (83--128%). The time point of the sample collection, the definition of antithrombin deficiency, and the different selection of patients are the several factors that may affect the frequency of antithrombin deficiency ([@B8]; [@B11]). The high prevalence of antithrombin deficiency in our study may be caused by these factors. The minor allele frequencies of the variant rs2227589 is 0.329 (gnomAD) in the East Asian population but not reported in the Chinese VTE population before. Our genotype data showed that the frequency of rs2227589 was also two times higher than that found in other studies. However, correlation analysis and comparison study of plasma antithrombin activity levels and genotype showed no significant association. The limitation of our study was the relatively small sample size because of the limited sources for us to recruit more patients. More patients recruited from multicenters may consolidate our findings and draw a more reliable conclusion. A study in a Spanish Caucasian population showed that healthy carriers of the rs2227589 SNP T allele had slightly but significantly lower anticoagulant activity with low antithrombin levels ([@B1]). Moreover, rs2227589 with haplotype in the *SERPINC1* gene of *FV Leiden* carriers showed significantly decreased antithrombin levels ([@B36]). However, another familial study showed that both rs2227589 carriers and noncarriers have low antithrombin levels ([@B6]). Thus, variations located in the coding regions of *SERPINC1* but not the rs2227589 (C \> T) located in the intron may cause antithrombin deficiency. Thus, whether there is an association between rs2227589 and antithrombin levels requires further investigation. The functional consequences of *SERPINC1* rs2227589 polymorphism might be directly caused by the regulatory effects of this genetic change or caused by other genetic variants linked to the rs2227589 polymorphism. Nevertheless, our study showed consistency with previous studies in that T allele carriers of VTE had slightly lower antithrombin levels, although this was not significant.

Our meta-analysis showed a significant association between rs2227589 and the risk of VTE in additive and dominant genetic models. Indeed, in our initial recruitment, we have recruited 225 patients. Our study showed that the genotyping distributions of rs2227589 in Chinese VTE and PTE groups are similar. When we included all of the 225 patients for meta-analysis, we found that the outcomes of meta-analysis (see [**Supplemental Tables 2**](#SM5){ref-type="supplementary-material"}, [**3**](#SM5){ref-type="supplementary-material"} and figures for the reanalyzed data) were consistent with the ones using 101 patients for analysis, suggesting the reliability of our findings. Genome-wide and familial case association studies have shown that numerous common or rare variants contribute to the risk of VTE ([@B37]). For common variants, a GWAS study already identified polymorphisms associated with the risk of DVT, such as *CYP4V2* (rs13146272), *SERPINC1* (rs2227589), and *GP6* (rs1613662) ([@B5]; [@B40]). Our study showed that carriers with low frequent TT genotype had a much higher risk of VTE based on the recessive model. The first GWAS reported by Bezemer et al. showed that carriers with the low-frequency T allele have a modest thrombotic risk in LETS, MEGA-1, and MEGA-2 case-control studies ([@B5]). This finding was later confirmed in the study by [@B3]. However, other studies failed to find any association between rs2227589 (*SERPINC1*) and VTE ([@B40]; [@B10]; [@B14]; [@B7]; [@B17]). Thus, whether rs2227589 plays any role in the risk of VTE remains controversial.

In conclusion, our study showed that variant rs2227589 is associated with an increased risk of PTE in a Chinese population. However, there appears to be no correlation with antithrombin deficiency in PTE. Further validation by employing a larger sample size and multiple-center studies may provide a more reliable conclusion of the association. Pooled systematic analysis showed a significant association between rs2227589 and the risk of VTE in the additive and dominant genetic models of multiple populations. As the contribution of rs2227589 to the risk of VTE may vary with different PTE ethnicities, further investigations into the genetic risk factors and phenotype interactions would be needed to improve the prognosis, prevention, and genetic counseling for populations at high risk of VTE.
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